BS_53CTGDQG
Meningioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Meningioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Meningioma
- overall_survival_months
- 194.94086727989486
- age_years
- 14.879
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.470
- ALLOGRAFT_REJECTION+0.428
- INTERFERON_GAMMA_RESPONSE+0.426
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.409
- IL6_JAK_STAT3_SIGNALING+0.406
- APOPTOSIS+0.378
- COAGULATION+0.339
- INFLAMMATORY_RESPONSE+0.333
- PROTEIN_SECRETION+0.330
- UV_RESPONSE_DN+0.302
Top 10 suppressed
- G2M_CHECKPOINT-0.320
- E2F_TARGETS-0.312
- HEDGEHOG_SIGNALING-0.264
- MYC_TARGETS_V2-0.217
- MITOTIC_SPINDLE-0.200
- SPERMATOGENESIS-0.192
- PANCREAS_BETA_CELLS-0.170
- DNA_REPAIR-0.109
- MYC_TARGETS_V1-0.103
- UV_RESPONSE_UP-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_Y3G1X98S | Meningioma | — | 0.915 |
| 2 | BS_10APZRVT | Meningioma | — | 0.905 |
| 3 | BS_KF0ZXDER | Meningioma | — | 0.896 |
| 4 | BS_THSPSG2Z | Meningioma | — | 0.890 |
| 5 | BS_VJAC9H58 | Schwannoma | — | 0.886 |
| 6 | MDT-AP-2021 | Med | Medulloblastoma | 0.885 |
| 7 | BS_JGPR9SR2 | Meningioma | — | 0.881 |
| 8 | BS_Q79NP5YY | pilocytic astrocytoma | — | 0.879 |
| 9 | BS_F8N6CFQE | low-grade glioma | — | 0.877 |
| 10 | BS_014EVM2D | low-grade glioma | — | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.428 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.426 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.409 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.406 | Inavolisib | — uncovered |
| APOPTOSIS | 0.378 | Idelalisib | — uncovered |
| COAGULATION | 0.339 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.333 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.302 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.293 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.267 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.263 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.238 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.228 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.223 | Inavolisib | — uncovered |
| COMPLEMENT | 0.213 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.209 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.199 | Inavolisib | — uncovered |